Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease

被引:38
作者
Chellappan, Sripriya [1 ]
Kairys, Visvaldas [1 ]
Fernandes, Miguel X. [1 ]
Schiffer, Celia [1 ]
Gilson, Michael K. [1 ]
机构
[1] Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA
关键词
resistance; AIDS; drug design; mutant; docking;
D O I
10.1002/prot.21431
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Crystallographic data show that various substrates of HIEV protease occupy a remarkably uniform region within the binding site; this region has been termed the substrate envelope. It has been suggested that an inhibitor that fits within the substrate envelope should tend to evade viral resistance because a protease mutation that reduces the affinity of the inhibitor will also tend to reduce the affinity of substrate, and will hence decrease the activity of the enzyme. Accordingly, inhibitors that fit the substrate envelope better should be less susceptible to clinically observed resistant mutations, since these must also allow substrates to bind. The present study describes a quantitative measure of the volume of a bound inhibitor falling outside the substrate envelope, and observes that this quantity correlates with the inhibitor's losses in affinity to clinically relevant mutants. This measure may thus be useful as a penalty function in the design of robust HIV protease inhibitors.
引用
收藏
页码:561 / 567
页数:7
相关论文
共 21 条
[1]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[2]  
CHEN ZG, 1994, J BIOL CHEM, V269, P26344
[3]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[4]   A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].
Hammer, SM ;
Squires, KE ;
Hughes, MD ;
Grimes, JM ;
Demeter, LM ;
Currier, JS ;
Eron, JJ ;
Feinberg, JE ;
Balfour, HH ;
Dayton, LR ;
Chodakewitz, JA ;
Fischl, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733
[5]   Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease [J].
Kaldor, SW ;
Kalish, VJ ;
Davies, JF ;
Shetty, BV ;
Fritz, JE ;
Appelt, K ;
Burgess, JA ;
Campanale, KM ;
Chirgadze, NY ;
Clawson, DK ;
Dressman, BA ;
Hatch, SD ;
Khalil, DA ;
Kosa, MB ;
Lubbehusen, PP ;
Muesing, MA ;
Patick, AK ;
Reich, SH ;
Su, KS ;
Tatlock, JH .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (24) :3979-3985
[6]   ABT-538 IS A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AND HAS HIGH ORAL BIOAVAILABILITY IN HUMANS [J].
KEMPF, DJ ;
MARSH, KC ;
DENISSEN, JF ;
MCDONALD, E ;
VASAVANONDA, S ;
FLENTGE, CA ;
GREEN, BE ;
FINO, L ;
PARK, CH ;
KONG, XP ;
WIDEBURG, NE ;
SALDIVAR, A ;
RUIZ, L ;
KATI, WM ;
SHAM, HL ;
ROBINS, T ;
STEWART, KD ;
HSU, A ;
PLATTNER, JJ ;
LEONARD, JM ;
NORBECK, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2484-2488
[7]   CRYSTAL-STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME [J].
KIM, EE ;
BAKER, CT ;
DWYER, MD ;
MURCKO, MA ;
RAO, BG ;
TUNG, RD ;
NAVIA, MA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (03) :1181-1182
[8]   Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor [J].
King, NM ;
Prabu-Jeyabalan, M ;
Nalivaika, EA ;
Wigerinck, P ;
de Béthune, MP ;
Schiffer, CA .
JOURNAL OF VIROLOGY, 2004, 78 (21) :12012-12021
[9]   Combating susceptibility to drug resistance: Lessons from HIV-1 protease [J].
King, NM ;
Prabu-Jeyabalan, M ;
Nalivaika, EA ;
Schiffer, CA .
CHEMISTRY & BIOLOGY, 2004, 11 (10) :1333-1338
[10]   NOVEL BINDING MODE OF HIGHLY POTENT HIV-PROTEINASE INHIBITORS INCORPORATING THE (R)-HYDROXYETHYLAMINE ISOSTERE [J].
KROHN, A ;
REDSHAW, S ;
RITCHIE, JC ;
GRAVES, BJ ;
HATADA, MH .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (11) :3340-3342